Status epilepticus (SE) is a serious neurologic condition with high morbidity and mortality rates. This study aimed to develop and validate a risk score that is predictive of mortality in patients with SE using clinical factors without electrocardiography. The inclusion criteria of this study were all patients diagnosed with SE and treated between 2005 and 2015. We retrospectively searched for eligible patients using the International Classification of Diseases, Tenth Revision (ICD-10) code for SE (G41) in the national Universal Health Coverage database. The outcome was death at discharge or within 30 days after discharge. Factors-associated death was analyzed using stepwise logistic regression analysis. Risk scores were developed based on the final logistic regression model. The final model was also validated. There were 10 924 patients used for model development and 10 808 used for model validation. The formula to determine the risk score for SE mortality was 5 × shock + 4 × age over 60 years old + 3.5 × heart diseases + 3 × acute renal failure + 3 × septicemia + 2.5 × central nervous system infection + 2.5 × age 41-60 years old + 2 × cancer + 2 × chronic renal failure + 1.5 × age 21-40 years old + 1 × pneumonia + 1 × respiratory failure + 1 × anemia. The risk scores of greater than 4 indicated risk for mortality with a sensitivity of 78.20% and specificity of 75.38%. The area under the receiver-operating characteristic (ROC) curve for death in the final model was 83.59%. The area under the ROC curve for the model validation group was 83.52%. SE patients who had a risk score of 4 or more were at high risk for death. Physicians should be aware of the high mortality rate in these particular patients.
Summary
Status epilepticus (SE) is a serious neurologic condition with high morbidity and mortality rates. This study aimed to develop and validate a risk score that is predictive of mortality in patients with SE using clinical factors without electrocardiography. The inclusion criteria of this study were all patients diagnosed with SE and treated between 2005 and 2015. We retrospectively searched for eligible patients using the International Classification of Diseases, Tenth Revision (ICD-10) code for SE (G41) in the national Universal Health Coverage database. The outcome was death at discharge or within 30 days after discharge. Factors-associated death was analyzed using stepwise logistic regression analysis. Risk scores were developed based on the final logistic regression model. The final model was also validated. There were 10 924 patients used for model development and 10 808 used for model validation. The formula to determine the risk score for SE mortality was 5 × shock + 4 × age over 60 years old + 3.5 × heart diseases + 3 × acute renal failure + 3 × septicemia + 2.5 × central nervous system infection + 2.5 × age 41-60 years old + 2 × cancer + 2 × chronic renal failure + 1.5 × age 21-40 years old + 1 × pneumonia + 1 × respiratory failure + 1 × anemia. The risk scores of greater than 4 indicated risk for mortality with a sensitivity of 78.20% and specificity of 75.38%. The area under the receiver-operating characteristic (ROC) curve for death in the final model was 83.59%. The area under the ROC curve for the model validation group was 83.52%. SE patients who had a risk score of 4 or more were at high risk for death. Physicians should be aware of the high mortality rate in these particular patients.
| INTRODUCTION
Status epilepticus (SE) is an emergency neurologic condition with high morbidity and mortality rates. [1] [2] [3] It is associated with an estimated mortality rate of up to 40%, even in developed countries. [4] [5] [6] [7] [8] [9] [10] Furthermore, the mortality rates have not decreased during the past decade despite advancements in treatment and knowledge. [11] [12] [13] [14] Several factors have been reported to be associated with mortality in SE such as age over 60 years, nonconvulsive seizures, and prolonged seizures (over 1 hour). 4, 15, 16 Currently, there are 2 predictive models for SE mortality: the Status Epilepticus Severity Score (STESS) and the Epidemiology-Based Mortality Score in Status Epilepticus (EMSE). 17, 18 Both models were effective and reliable 17 but
were conducted on only 154 and 92 patients, respectively. In addition, the latter score uses electrocardiography (EEG) findings as one of its predictors. In developing countries, EEG may not be available in all health care facilities. This study aimed to create a predictive model that is userfriendly and can be conducted on a large study population using mainly clinical factors as studied variables.
| MATERIALS AND METHODS
This was a retrospective cohort study that was conducted using the Thai national Universal Health Coverage (UC) database. Universal Health Coverage is a kind of basic health insurance that is provided to Thai nationals and that covers approximately 75% of Thai citizens. The eligibility criteria for this study were that all patients had been diagnosed with SE and had been admitted to any hospital between 2005 and 2015. We searched the UC database using the International Classification of Diseases, Tenth Revision (ICD-10) code of G41. Clinical data of all eligible patients were retrospectively reviewed. Using the Ministry of the Interior's database, we were able to review patient health status at 30 days after hospital discharge. The outcomes examined by this study were death at discharge and death at 30 days after discharge. The variables examined were age, sex, comorbidities, and complications of SE.
All eligible patients were divided into 2 groups using a simple random sampling method. The first group was used to develop a model to predict mortality in SE patients (model development), whereas the second was used to validate the predictive model (model validation). Studied variables were used to calculate a P value and unadjusted odds ratio (OR) to predict mortality in cases of SE using univariate logistic regression analysis. If the P value was <0.25, it was subsequently included in stepwise multivariate logistic regression analysis. The results were reported as adjusted OR and 95% confidence interval (CI). The area under a receiver-operating characteristic (ROC) curve of the final model to predict mortality in SE patients was reported.
The coefficients from each significant factor derived from multivariate logistic regression analysis were used to create a risk score for SE mortality. The lowest coefficient was rounded up to 0.5 or 1.0 and recorded as a risk score of 1. The risk scores of other factors were calculated as their coefficient divided by the lowest coefficient, then rounded up by 0.5 points. The individual risk score formula was created by the summation of all significant factors multiplied by their risk score. Cutoff point risk scores were derived from the association with mortality according to logistic regression analysis. An appropriate cutoff point risk score was selected to provide a sensitivity and specificity of 70%-80%.
The second study population was used to validate the predictive model for SE mortality. The ROC curve of the predictive model and sensitivity/specificity of the selected cutoff risk score were calculated using the validation study population. Subgroup analysis in SE patients under 18 years of age and over 60 years of age was performed using the same processes. All analysis was performed using STATA software (College Station, TX, USA).
| RESULTS
During the study period, there were 21 732 SE patients who met the study criteria. Those patients were divided into 2 groups using a simple random sampling method (10 924 patients for model development and 10 808 patients for model validation 
Key points
• Using a large database, this study develops and validates a risk score that is predictive of mortality in patients with status epilepticus • The formula to determine the risk score for status epilepticus mortality is developed using clinical factors without an electrocardiography parameter • The risk scores for status epilepticus mortality had good diagnostic properties for both the model development and model validation dataset group, respectively. All other variables, including comorbidities and complications of SE, were comparable between the 2 groups (Table 1 ).
In the first study group, the mortality rate was 16.67% (1821 of 10 924 patients). Three factors were associated with a mortality rate over 50%: heart disease (57.89%), acute renal failure (65.39%), and shock (77.89%), as shown in Table 2 . Eleven independent factors associated with death in SE patients remained in the final model (Table 3 ).
The area under the ROC curve in the final model was 83.59%, as shown in Figure 1 and Table 4 .
Anemia had the lowest coefficient of 0.46, which was rounded up to 0.5 and assigned a risk score of 1. The risk scores of other significant factors were calculated by dividing their coefficients by 0.5. The highest summation of all risk scores was 28 (Table 3) . A cutoff risk score of 4 was associated with mortality with a sensitivity of 78.20% and specificity of 75.38%. The model predictive of mortality in cases of SE was validated in the population of 10 808 patients (Table 4 ). In terms of subgroup analysis, the results of the predictive model are shown in Table 4 for those under 18 years and over 60 years of age.
| DISCUSSION
This study developed the risk score predictive for SE mortality using clinical parameters. Note that the EEG The percentage of each variable was calculated from the total number of patients with the particular variable. *The P value derived from univariate logistic regression analysis.
parameter was not included in the model. Therefore, this model may be suitable for developing countries or healthcare facilities where EEG is not available. Even without the EEG, the model had high predictive properties (sensitivity of 78.20% and specificity of 75.38%). It was also validated using a large population (10 808 patients). The validated model also had high sensitivity and specificity (77.87% and 74.93%, respectively) as shown in Table 4 . Compared with previous predictive models, the study population in this study was larger (STESS n = 154, EMSE n = 92). This model is easily to perform because seizure type, EEG, and imaging are not needed. Although the STESS model requires seizure type and EEG information in case of nonconvulsive SE and EMSE model is more complicated, requires relatively more time and always needs advanced imaging/EEG to fulfill the model, our mode is less time-consuming to use. Without EEG, there were 3 mainly clinical factors for SE mortality including advanced age, comorbidities, and the presence of SE complications. The independent comorbidities were heart disease, central nervous system (CNS) infection, cancer, chronic renal failure, and anemia, whereas the significant SE complications were shock, acute renal failure, septicemia, pneumonia, and respiratory failure. Advanced age has been reported to be the predictor for SE mortality in several studies including both those that use STESS and those that use EMSE predictive models. 4, 15, 16, 18 One previous study, for example, showed that the mortality rate of SE patients over 60 years old was almost 3 times higher than that of younger adults (38% vs 14%). 4 A study using the STESS model also showed that for each 1-year increase in age, risk of SE mortality increased by 1.03 times. 15 In the present study, the age group exhibited a dose-response pattern in terms of increasing in mortality risk. The adjusted ORs for ages 21-40, 41-60, and >60 years were 2.13, 2.95, and 7.02, respectively (as shown in Table 3 ). The high SE mortality rate for patients of advanced age can be explained by the fact that SE in these cases was caused mostly by acute | 185 stroke or anoxic brain damage, which have high mortality rates. 4 Among 9 comorbidities that were found to be significant according to univariate logistic regression analysis (Table 2) , only 5 factors were independently associated with SE mortality. The highest impact comorbidity (resulting a risk score of 3.5) was heart disease (excluding ischemic heart disease), whereas anemia had the lowest risk score (1), as shown in Table 3 . CNS infection, heart disease, cancers, and chronic renal failure were 3 comorbidities that were found to be significant predictors for SE mortality, which is similar to previous findings. 18, 19 In addition, the strengths of these variables are comparable to those found in the EMSE study. In the EMSE study, cancer and renal disease both yielded an EMSE score of 20. 18 In this present study, cancer and renal disease yielded adjusted ORs of 2.81 and 2.39, respectively (Table 3) . Diabetes and ischemic heart disease were not found to be significant predictors of mortality in this study but were found to be significant in the EMSE study. These 2 factors had the smallest impact in the EMSE study (with a score of 10). These factors may not be found to be significant in a study with a larger sample size, like in this present study. In addition, the EMSE study specifically examined cases of myocardial infarction. In the present study, we searched for data using a wider range of ischemic heart diseases (I20-I25). In one study on refractory SE, patients who received thiopental had higher proportions of anemia than those with midazolam (42% vs 16%; P value .04). 20 These findings indicate that anemia may be a predictor of refractory SE. However, the explanation for this finding is still unknown.
20
Neither the STESS model nor the EMSE model includes complications of SE. 15, 18 This study found that 5 SE complications (Table 3) were independently associated with SE mortality, as reported previously. [21] [22] [23] Our subgroup analysis showed slightly different predictors in those younger than 18 years or over 60 years old (Table 4 ). All models were validated by another study population with good correlation and diagnostic properties ( Table 4) . The strengths of this study were that (1) there was a large study sample size, (2) the predictive model was analyzed using clinical data, (3) the individual risk score for SE mortality was user-friendly, (4) the risk scores were produced for extreme ages (<18 years and >60 years), (5) the cutoff risk scores had good sensitivities and specificities, and (6) the models were validated. However, there were some limitations. First, clinical data of each individual patient, such as baseline laboratory results, were not studied. Second, some factors were not included in the study such as HIV status or metastatic stage of cancer. Third, the predictive model did not include causes of the disease or EEG data. Moreover, the score was developed and validated on a similar population; an external validation in other populations is needed. The individual risk score for SE mortality was (1.5, 2.5, or 4) × age group + 5 × shock + 3.5 × heart diseases + 3 × acute renal failure + 3 × septicemia + 2.5 × central nervous system (CNS) infection + 2.5 × age 41-60 years old + 2 × cancer + 2 × chronic renal failure + 1.5 × age 21-40 years old + 1 × pneumonia + 1 × respiratory failure + 1 × anemia. The individual risk score for SE mortality for those younger than 18 years of age was 4.5 × acute renal failure + 3.5 × heart diseases + 3.5 × shock + 3 × cancer + 2.5 × brain tumor + 1.5 × central nervous system (CNS) infection + 1 × anemia + 1 × congenital + 1 × septicemia. The individual risk score for SE mortality for those with age over 60 years was 3.5 × septicemia + 3.5 × shock + 3.5 × central nervous system (CNS) infection + 2.5 × acute renal failure + 2 × chronic renal failure + 2 × heart diseases + 1.5 × respiratory failure + 1.5 × pneumonia + 1 × anemia; the variable value was 1 if present and 0 if absent.
T A B L E 4
Characteristics of risk score model in predicting mortality in status epilepticus patients diagnosed between 2005 and 2015 from the Thai national database categorized by age group
In conclusion, the clinical predictive model for SE mortality was reproduced using the national database. Advanced age, comorbidities, and complications of SE were independent factors for SE mortality. This prediction tool was developed using clinical parameters and did not required EEG, and thus it may be suitable for healthcare facilities where EEG is not available.
